By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Enterprise Replace First Website Activated for Section 3 OVATION 3 Trial of IMNN-001 in Ovarian Most cancers On Might 8, 2025, Imunon, Inc. (NASDAQ:IMNN) introduced that the primary trial web site for the Section 3 OVATION 3 trial has been activated and is able … Read more
Eve Hill, companion at Brown, Goldstein & Levy, participated in a convening workshop on “Born-Accessible Design for Digital Accessibility: Defining, Scoping Strategies, and Setting a Analysis Agenda” on Might 5-6 on the Harvard Radcliffe Institute in Boston. Eve, together with different leaders in incapacity and expertise, mentioned what it means for expertise to be “born … Read more
By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Prescription drugs (NASDAQ:TELO) is a preclinical stage biopharmaceutical firm creating a product designed to elongate the DNA’s protecting telomere caps. Beforehand reported preclinical assessments have proven proof that Telomir-1, the corporate’s major remedy, can lengthen telomeres and preliminary animal testing illustrates the potential … Read more
Trade stakeholders seeking to maintain tempo with market challenges might discover range in analysis the important thing to long-term success and resilience. A mess of various views, concepts, and options can improve innovation and strategic outcomes. Be part of The Institutes for a webinar panel dialogue of methods for creating inclusive analysis areas, addressing biases, … Read more
By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) has been beneath the management of a brand new CEO for simply over a 12 months, with Mr. Hashad not too long ago issuing a letter to shareholders marking the milestone. We now have been telling buyers in regards to the nice … Read more
